Loading...
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer, S Powell, M Mileshkin, L Katsaros, D Bessette, P Haie-Meder, C Ottevanger, P Ledermann, J Khaw, P Colombo, A
de Boer, S
Powell, M
Mileshkin, L
Katsaros, D
Bessette, P
Haie-Meder, C
Ottevanger, P
Ledermann, J
Khaw, P
Colombo, A
Citations
Altmetric:
Abstract
Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer.
Authors
de Boer, S
Powell, M
Mileshkin, L
Katsaros, D
Bessette, P
Haie-Meder, C
Ottevanger, P
Ledermann, J
Khaw, P
Colombo, A
Fyles, A
Baron, M
Jürgenliemk-Schulz, I
Kitchener, Henry C
Nijman, H
Wilson, G
Brooks, S
Carinelli, S
Provencher, D
Hanzen, C
Lutgens, L
Smit, V
Singh, N
Do, V
D'Amico, R
Nout, R
Feeney, A
Verhoeven-Adema, KW
Putter, H
Creutzberg, C
Powell, M
Mileshkin, L
Katsaros, D
Bessette, P
Haie-Meder, C
Ottevanger, P
Ledermann, J
Khaw, P
Colombo, A
Fyles, A
Baron, M
Jürgenliemk-Schulz, I
Kitchener, Henry C
Nijman, H
Wilson, G
Brooks, S
Carinelli, S
Provencher, D
Hanzen, C
Lutgens, L
Smit, V
Singh, N
Do, V
D'Amico, R
Nout, R
Feeney, A
Verhoeven-Adema, KW
Putter, H
Creutzberg, C
Description
Date
2018-03
Publisher
Collections
Files
Keywords
Type
Article
Citation
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. 2018, 19 (3):295-309 Lancet Oncol.